This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cardiomyopathy심근병증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I42 (cardiomyopathy) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsDilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), left ventricular noncompaction cardiomyopathy (LVNC)
C. Adult onsetHypertrophic cardiomyopathy is the most common cause of sudden death in young adults; dilated cardiomyopathy is commonly diagnosed in the 40s–60s; restrictive cardiomyopathy and ARVC present at various ages.
1. History1957 WHO classification, Goodwin's three-category classification of cardiomyopathy established (1972), AHA/ESC classification revisions (2006, 2008); rise of gene-based precision medicine
2. CausesInherited (sarcomere variants, cytoskeletal variants), acquired (post-myocarditis, toxins, pregnancy, ischemia), mixed; includes unknown cause (idiopathic)
3. GeneticsHCM: MYH7, MYBPC3 variants (about 80% of inherited cases); DCM: more than 50 genes including TTN, LMNA, SCN5A; ARVC: DSP, PKP2, DSG2
4. General epidemiologyHCM prevalence 1/500; DCM prevalence 1/250; cardiomyopathy overall is a major indication for heart transplantation
5. PathophysiologySarcomere dysfunction → impaired energy metabolism → myocardial hypertrophy and fibrosis; TTN variants → cytoskeletal disruption → dilatation and reduced systolic function
6. SymptomsHCM: exertional syncope, chest pain, dyspnea, sudden death; DCM: progressive heart failure; RCM: reduced exercise tolerance, right heart failure
7. SignsHCM: systolic outflow tract murmur (increased with Valsalva), bisferiens pulse; DCM: cardiomegaly, S3, signs of heart failure
8. ScreeningEchocardiography when ECG abnormalities or heart murmurs are present; family history review and screening of first-degree relatives; ECG screening of athletes
9. DiagnosisEchocardiography, cardiac MRI (assessment of myocardial fibrosis, hypertrophy and function), genetic testing, ECG, Holter monitor
10. TreatmentHCM: beta-blockers, non-vasodilating calcium channel blockers, mavacamten; DCM: GDMT; ICD for high risk of sudden death; surgical and transcatheter septal reduction therapy
11. PrognosisHCM annual mortality about 1%; DCM 5-year survival about 50–70%; LMNA-variant DCM has high risk of arrhythmia and sudden death
12. PreventionFamily history review and genetic testing; exercise restriction in HCM; avoidance of drug and toxin causes of cardiomyopathy; sudden death risk assessment and ICD
13. ReferencesMaron BJ et al. Contemporary Definitions and Classification of the Cardiomyopathies … and 9 other papers

1. History

The history of cardiomyopathy is closely tied to the development of heart disease classification systems. Until the early 20th century, the concept of a primary disease of the myocardium itself was not established, and myocardial dysfunction was mostly understood as a secondary consequence of coronary artery disease or valvular disease. In 1957 Wallace Brigden first proposed the concept of "primary myocardial disease", and in 1968 the WHO gave the first official definition of cardiomyopathy as "myocardial disease of unknown or uncertain cause".

In 1972 John Goodwin classified cardiomyopathy according to morphophysiological characteristics as dilated, hypertrophic and obstructive, and this classification system remains the basis of clinical practice today. In the 1980s, advances in molecular genetics began to reveal that hypertrophic cardiomyopathy is an inherited disease caused by variants in sarcomere protein genes. In 1990 Geisterfer-Lowrance et al. first reported that variants in the MYH7 (beta-myosin heavy chain) gene cause familial hypertrophic cardiomyopathy.

In the 2000s, advances in genetic analysis technology led to the discovery of dozens of causal genes in dilated cardiomyopathy, including TTN (titin), LMNA (lamin A/C) and SCN5A. The AHA in 2006 and the ESC in 2008 each published revised cardiomyopathy classification systems. In the 2020s, sarcomere function–modulating drugs such as mavacamten were developed, making pathophysiology-based treatment possible for the first time in hypertrophic cardiomyopathy. In addition, as the beneficial effects of SGLT2 inhibitors in dilated cardiomyopathy were confirmed, the paradigm of drug therapy for cardiomyopathy is changing.


2. Causes

The causes of cardiomyopathy are broadly classified as inherited, acquired and mixed. Hypertrophic cardiomyopathy (HCM) is an inherited disease caused by sarcomere protein gene variants in about 50–60%. The most common causal genes are MYH7 (about 35%) and MYBPC3 (about 40%), inherited in an autosomal dominant manner. About 20–35% of dilated cardiomyopathy (DCM) is inherited, and more than 50 causal genes are known, including TTN (titin, about 15–25%), LMNA (lamin A/C), MYH7, SCN5A and RBM20. Acquired causes include post-myocarditis, alcohol, toxins (anticancer drugs such as anthracyclines), postpartum cardiomyopathy and tachycardia-induced cardiomyopathy.

Restrictive cardiomyopathy (RCM) is characterized by impaired myocardial relaxation and is classified as idiopathic (primary) or secondary (amyloidosis, sarcoidosis, hemochromatosis, glycogen storage disease, etc.). Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease caused mainly by variants in desmosomal protein genes (PKP2, DSP, DSG2, etc.), characterized by replacement of right ventricular myocardium with fatty and fibrous tissue. Left ventricular noncompaction cardiomyopathy (LVNC) is a congenital form arising from abnormal formation of endocardial trabeculae during fetal life. Peripartum cardiomyopathy (PPCM) is a distinctive form of DCM occurring in the last month of pregnancy or within 5 months after delivery.


3. Genetics

The genetics of cardiomyopathy have advanced rapidly over the past 30 years. The causal genes of hypertrophic cardiomyopathy (HCM) almost all encode components of sarcomere proteins (contractile apparatus), and MYH7 (β-myosin heavy chain) and MYBPC3 (cardiac myosin-binding protein C) account for about 80% of all inherited HCM. Many other sarcomere genes are involved, including TNNT2, TNNI3, TPM1, MYL2 and MYL3. HCM is most commonly autosomal dominant, and penetrance and variable expressivity vary widely even with the same mutation.

The most common causal gene in dilated cardiomyopathy (DCM) is TTN (titin), accounting for about 15–25% of familial DCM. TTN is the largest protein in the sarcomere and provides elastic recoil and mechanosensing. LMNA variants (lamin A/C deficiency) account for about 5–10% of DCM and are poor-prognosis variants with a particularly high risk of conduction disorders, atrial fibrillation and sudden death. SCN5A (sodium channel) variant DCM also carries a high arrhythmia risk. The causal genes of ARVC mostly encode desmosomal proteins (PKP2, DSP, DSG2, DSC2, JUP), and PKP2 (plakophilin-2) variants are the most common. Genetic testing is important for screening first-degree relatives and for risk stratification, and genetic testing with family history review and genetic counseling should be considered in all patients with cardiomyopathy.


4. General epidemiology

Cardiomyopathy is an important underlying cause of heart failure and heart transplantation. The prevalence of hypertrophic cardiomyopathy (HCM) is about 1 in 500 (0.2%), making it the most common inherited heart disease in adults. However, considering that many cases are asymptomatic or mild and go undiagnosed, the actual prevalence is estimated to be higher. HCM accounts for the highest proportion of causes of sudden death in young people aged 35 and under, including athletes.

The prevalence of dilated cardiomyopathy (DCM) is about 1 in 250 (0.4%), the most common of the cardiomyopathies. DCM is the underlying cause in about 30–40% of heart failure patients and one of the main indications for heart transplantation. The annual incidence is about 5–8 per 100,000 population. It is 2–3 times more common in men. Restrictive cardiomyopathy (RCM) is the rarest form of cardiomyopathy, accounting for less than about 5%. The prevalence of ARVC is estimated at about 1 in 1,000–5,000 and is closely associated with sudden death in competitive athletes.


5. Pathophysiology

The pathophysiology of hypertrophic cardiomyopathy (HCM) begins mainly with sarcomere protein dysfunction. MYH7 or MYBPC3 variants mechanobiologically alter sarcomere contractile function (excessive contractility or reduced energy efficiency), and myocardial hypertrophy progresses as a compensatory response. Impaired energy metabolism, oxidative stress and overactivation of the TGF-β signaling pathway promote myocardial fibrosis (interstitial fibrosis). Hypertrophied myocardium and fibrosis cause left ventricular diastolic dysfunction, and when left ventricular outflow tract obstruction (LVOTO) develops, the hemodynamic burden increases.

The pathophysiology of dilated cardiomyopathy (DCM) varies with the cause. In TTN-variant DCM, the elastic support structure of the sarcomere is damaged, making cardiomyocytes vulnerable to mechanical stress, and cell damage and death accumulate through repeated contraction and relaxation. In LMNA-variant DCM, nuclear envelope abnormalities cause impaired mechanosensing signal transduction, overactivation of ERK signaling and increased apoptosis. Common to all, neurohormonal activation (RAAS, sympathetic nervous system activation), cytokines (TNF-α, IL-6) and myocardial oxidative damage contribute to disease progression.


6. Symptoms

The symptoms of hypertrophic cardiomyopathy (HCM) vary. Many cases are mild or asymptomatic, but when symptoms are present, exertional dyspnea is the most common. Chest pain is due to increased oxygen demand of the hypertrophied myocardium and microvascular dysfunction. Syncope or presyncope is due to worsening of ventricular outflow tract obstruction or arrhythmia. Sudden cardiac death (SCD) due to ventricular fibrillation or ventricular tachycardia is the most serious consequence of HCM and is well known as a cause of sudden death in young athletes.

Dilated cardiomyopathy (DCM) is characterized by slowly progressive heart failure symptoms. Reduced exercise tolerance, fatigue and dyspnea (progressing from exertional to orthopnea to paroxysmal nocturnal dyspnea) are the main symptoms. Palpitations due to atrial fibrillation or ventricular arrhythmias and syncope are also common. In LMNA-variant DCM, conduction disorders (atrioventricular block, bundle branch block) may appear as preceding symptoms. In restrictive cardiomyopathy, reduced exercise tolerance and symptoms of right heart failure (leg edema, ascites, anorexia) are prominent, and both left and right filling pressures are increased.


7. Signs

The characteristic physical finding of hypertrophic cardiomyopathy (HCM) is a dynamic systolic murmur. It is a harsh systolic murmur heard at the lower left sternal border that increases with the Valsalva maneuver (reduced preload) or on standing and decreases with squatting or isometric exercise. A double apical impulse or a triple impulse due to delayed relaxation is palpable, and an S4 gallop is heard at the apex. Peripheral pulse abnormalities such as a bisferiens pulse due to ventricular septal hypertrophy may also be observed.

In dilated cardiomyopathy (DCM), cardiac enlargement (left ventricular hypertrophy) displaces the apical impulse laterally and downward and broadens it. An S3 gallop is heard at the apex, and a murmur of secondary mitral regurgitation may be present. As heart failure progresses, systemic signs of congestive heart failure appear, such as pulmonary edema (crackles), elevated jugular venous pressure, leg edema and ascites. In ARVC, signs of right heart failure and arrhythmias (ventricular tachycardia with left bundle branch block morphology) are characteristic.


8. Screening

Screening for cardiomyopathy mainly begins with family history, ECG abnormalities or detection of a heart murmur. Screening with ECG and echocardiography is recommended for first-degree relatives of patients with cardiomyopathy. Because HCM is autosomal dominant, 50% of a patient's first-degree relatives may carry the variant. Screening of athletes includes a 12-lead ECG in many countries and contributes to early detection of HCM and ARVC. In some European countries (Italy, etc.), ECG screening of competitive athletes is mandatory.

When familial cardiomyopathy is identified, it is recommended that the causal variant be confirmed by genetic testing and that phenotypic screening and genetic testing be performed systematically in families in which the variant is confirmed. Echocardiography is performed when the ECG shows left ventricular hypertrophy, repolarization abnormalities, Q waves, bundle branch block and the like. When alcoholic cardiomyopathy is suspected, taking a history of heavy drinking is important.


9. Diagnosis

Echocardiography is the first-line test for diagnosing cardiomyopathy. In HCM, the diagnostic criteria are a maximal left ventricular wall thickness ≥15 mm (or ≥13 mm with a family history), asymmetric hypertrophy (especially of the ventricular septum), systolic anterior motion of the anterior mitral leaflet (SAM), and a peak left ventricular outflow tract gradient ≥30 mmHg (at rest or provoked). DCM is characterized by left ventricular dilatation (LVEDD >60 mm or >32 mm/m²), global systolic dysfunction (LVEF <50%) and secondary mitral regurgitation.

Cardiac MRI excels at morphological classification, identification of the cause and assessment of fibrosis in cardiomyopathy. The LGE (late gadolinium enhancement) pattern is key to differentiating cardiomyopathy types: mid-wall LGE in hypertrophied segments in HCM; mid-wall or subendocardial non-infarct LGE in DCM; right ventricular myocardial fat deposition and LGE in ARVC. T1 mapping and extracellular volume fraction (ECV) are used to quantify diffuse fibrosis. Genetic testing is performed together with clinical diagnosis, and panel testing (50–100 or more cardiomyopathy genes) is recommended. Endomyocardial biopsy is performed when differentiation of infiltrative cardiomyopathy (amyloid, sarcoid) or identification of an inflammatory cause is needed.


10. Treatment

The goals of treatment of hypertrophic cardiomyopathy (HCM) are symptom relief and prevention of sudden death. In symptomatic cases, non-vasodilating beta-blockers (metoprolol, atenolol) or non-vasodilating calcium channel blockers (verapamil) are used as first-line drugs. Mavacamten, approved by the FDA in 2022, is the first pathophysiology-based treatment that selectively inhibits sarcomeric myosin ATPase and has shown reduced outflow tract gradients and improved symptoms in obstructive HCM. When ventricular outflow tract obstruction persists and the response to drug therapy is insufficient, surgical septal myectomy (Morrow procedure) or transcatheter alcohol septal ablation is performed. An ICD is implanted in high-risk patients according to sudden death risk assessment (5-year SCD risk calculator).

In dilated cardiomyopathy (DCM), GDMT is the foundation. Four-drug combination therapy with an ACE inhibitor (or ARB, ARNI), beta-blocker, MRA and SGLT2 inhibitor aims at reverse remodeling and reduced mortality. Anticoagulation is considered for atrial fibrillation, CRT (cardiac resynchronization therapy) for ventricular dyssynchrony, and ICD implantation for high-risk patients. In end-stage DCM refractory to medical therapy, heart transplantation or implantation of a mechanical circulatory support device (LVAD) is the final treatment.


11. Prognosis

The prognosis of cardiomyopathy varies greatly with type and cause. The annual mortality of HCM is low, at about 1%, when patients are followed at specialized centers. However, in high-risk patients at risk of sudden death (family history of sudden death, recurrent syncope, ventricular tachycardia, maximal wall thickness ≥30 mm, exercise-induced hypotension, extensive LGE), ICD implantation greatly improves prognosis. The 5-year survival of DCM has improved greatly compared with the past owing to advances in treatment, but is still about 50–70%. LMNA-variant DCM has a very high risk of conduction disorders, atrial fibrillation, ventricular tachycardia and sudden death, requiring early ICD implantation. TTN-variant DCM has a relatively better prognosis. The prognosis of ARVC is determined by the intensity of competitive exercise, arrhythmia burden and right ventricular function.


12. Prevention

Primary prevention of inherited cardiomyopathy is achieved through early genetic testing and phenotypic screening. In HCM patients and families, diagnosis is made before phenotypic expression through screening of first-degree relatives (echocardiography + genetic testing), and regular examinations are performed when ECG abnormalities are present or before sports participation. Restriction of competitive exercise in HCM patients is key to preventing sudden death. There is evidence that exercise restriction in ARVC patients slows disease progression and lowers arrhythmia risk.

To prevent acquired cardiomyopathy, avoiding causal factors is important. Because alcoholic cardiomyopathy can recover with abstinence, early detection and cessation of alcohol abuse are key. Before administering anticancer drugs (especially anthracyclines), cardiac function assessment, cardiotoxicity monitoring and cardioprotective strategies through cardio-oncology consultation are important. To prevent postpartum cardiomyopathy, appropriate medical care during pregnancy and early recognition of postpartum symptoms are needed.


13. References

  1. Maron BJ, Towbin JA, Thiene G, et al. (American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee). Contemporary Definitions and Classification of the Cardiomyopathies. Circulation. 2006;113(14):1807-1816. DOI: 10.1161/CIRCULATIONAHA.106.174287. PMID: 16567565.

  2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2008;29(2):270-276. DOI: 10.1093/eurheartj/ehm342. PMID: 17916581.

  3. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2020;76(25):e159-e240. DOI: 10.1016/j.jacc.2020.08.045. PMID: 33229116.

  4. McDonagh TA, Metra M, Adamo M, et al. (ESC Scientific Document Group). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368. PMID: 34447992.

  5. Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. Journal of Medical Genetics. 2013;50(4):228-239. DOI: 10.1136/jmedgenet-2012-101270. PMID: 23396983.

  6. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. New England Journal of Medicine. 2012;366(7):619-628. DOI: 10.1056/NEJMoa1110186. PMID: 22335739.

  7. Olivotto I, Oreziak A, Barriales-Villa R, et al. (EXPLORER-HCM study investigators). Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM). Lancet. 2020;396(10253):759-769. DOI: 10.1016/S0140-6736(20)31792-X. PMID: 32871100.

  8. Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal. 2015;36(14):847-855. DOI: 10.1093/eurheartj/ehu509. PMID: 25616645.

  9. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. (Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy). Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy. European Journal of Heart Failure. 2010;12(8):767-778. DOI: 10.1093/eurjhf/hfq120. PMID: 20675664.

  10. Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nature Reviews Disease Primers. 2019;5(1):32. DOI: 10.1038/s41572-019-0084-1. PMID: 31073128.